Talapatra Kaustav, Chitkara Garvit, Murali-Nanavati Sridevi, Gupte Ajinkya, Bardeskar Nikhil S, Behal Shruti, Shaikh Muzammil, Atluri Pooja
Nanavati Max Institute of Cancer Care, Nanavati Max Super Speciality Hospital, Mumbai, 400056 India.
Indian J Surg Oncol. 2024 Mar;15(1):63-70. doi: 10.1007/s13193-023-01824-7. Epub 2023 Oct 4.
The practice of boost to the tumor bed after treatment with oncoplastic breast-conserving surgery (BCS) remains variable. Using a survey, the present study evaluated the current practice of tumor bed boost administered in women after oncoplastic BCS. Actively practicing radiation oncologists across India were sent a questionnaire on the practice of adjuvant whole-breast radiotherapy and tumor bed boost after oncoplastic BCS via email and encouraged to participate. Of the 54 radiation oncologists who participated, most (98.1%) used a linear accelerator for radiotherapy. Hypofractionation was preferred by 59.26%, standard fractionation by 7.41%, and the remaining selected the fractionation strategy based on various patient factors. In addition, 83.33% participants reported that they always planned tumor boost, 51.85% preferred photons for the boost, and 75.93% administered sequential boost. The most common dose for the boost was 12.5 Gy in five fractions (40.74%). Most participants (77.78%) revealed that they used a combination of methods for identifying the tumor bed. With respect to clip placement, most surgeons (96%) at the participants' centers placed ≥ 4 clips at the tumor site, with both the base and margins being preferred by surgeons (81.48%) for placement. Finally, 12.96% participants revealed that the surgeons always involved them during surgical planning, whereas 7.4% participants reported that they always included the surgeons during radiotherapy planning, suggesting that radiation oncologists and oncoplastic surgeons do not involve each other during surgical and radiotherapy planning, possibly leading to suboptimal treatment. This may be attributed to the absence of guidelines regarding boost practices after oncoplastic BCS.
肿瘤整形保乳手术(BCS)治疗后对瘤床进行放疗的做法仍存在差异。本研究通过一项调查评估了肿瘤整形BCS术后女性患者瘤床放疗的当前实践情况。通过电子邮件向印度各地积极从业的放射肿瘤学家发送了一份关于肿瘤整形BCS术后辅助全乳放疗和瘤床放疗实践的问卷,并鼓励他们参与。在参与的54名放射肿瘤学家中,大多数(98.1%)使用直线加速器进行放疗。59.26%的人倾向于采用大分割放疗,7.41%的人倾向于标准分割放疗,其余的人根据各种患者因素选择分割策略。此外,83.33%的参与者报告说他们总是计划进行瘤床放疗,51.85%的人倾向于使用光子进行瘤床放疗,75.93%的人采用序贯放疗。瘤床放疗最常用的剂量是12.5 Gy,分5次给予(40.74%)。大多数参与者(77.78%)表示他们使用多种方法相结合来确定瘤床。关于钛夹放置,参与者所在中心的大多数外科医生(96%)在肿瘤部位放置≥4个钛夹,外科医生更倾向于在肿瘤基部和边缘放置钛夹(81.48%)。最后,12.96%的参与者表示外科医生在手术规划过程中总是会让他们参与,而7.4%的参与者报告说他们在放疗规划过程中总是会让外科医生参与,这表明放射肿瘤学家和肿瘤整形外科医生在手术和放疗规划过程中没有相互协作,这可能会导致治疗效果欠佳。这可能归因于缺乏关于肿瘤整形BCS术后放疗实践的指南。